{"id":"dasatinib-tablets","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Pleural effusion"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Headache"},{"rate":"15-25","effect":"Fatigue"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Rash"},{"rate":"10-15","effect":"Fluid retention"},{"rate":"variable","effect":"Myelosuppression"}]},"_chembl":{"chemblId":"CHEMBL1421","moleculeType":"Small molecule","molecularWeight":"488.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dasatinib inhibits the BCR-ABL fusion protein that drives chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It also inhibits SRC family kinases and other tyrosine kinases, providing a broader spectrum of activity than earlier-generation ABL inhibitors. This multi-targeted approach can overcome some resistance mechanisms and provide activity against certain BCR-ABL mutations.","oneSentence":"Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:09.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML), chronic phase, accelerated phase, and blast crisis"},{"name":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)"}]},"trialDetails":[{"nctId":"NCT05653258","phase":"PHASE2, PHASE3","title":"Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-10-17","conditions":"Obesity, Healthy Lifestyle","enrollment":160},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT07342491","phase":"PHASE1","title":"Dasatinib for HIV-1 Reservoir Reduction","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-03-02","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT05506488","phase":"PHASE1, PHASE2","title":"Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-05","conditions":"NAFLD, NASH With Fibrosis, Liver Fibrosis","enrollment":30},{"nctId":"NCT05007873","phase":"PHASE2","title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":70},{"nctId":"NCT06018467","phase":"PHASE2","title":"Senolytics to Improve Osteoporosis Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-09-06","conditions":"Osteopenia, Osteoporosis, Age-related Bone Loss","enrollment":120},{"nctId":"NCT05780073","phase":"PHASE2","title":"Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment","status":"COMPLETED","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2023-10-16","conditions":"HIV Infection Primary","enrollment":60},{"nctId":"NCT00777036","phase":"PHASE2","title":"A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03-20","conditions":"Leukemia","enrollment":133},{"nctId":"NCT02848131","phase":"PHASE2","title":"Senescence in Chronic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2016-07","conditions":"Chronic Kidney Disease","enrollment":30},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT05944783","phase":"PHASE4","title":"Bioequivalence Studies of Dasatinib 100 Mg","status":"NOT_YET_RECRUITING","sponsor":"Centro de Atencion e Investigacion Medica","startDate":"2025-09-01","conditions":"Myeloma Multiple","enrollment":46},{"nctId":"NCT02652052","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplant Survivors Study","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-03-01","conditions":"Stem Cell Transplant","enrollment":9},{"nctId":"NCT04147533","phase":"PHASE2","title":"Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masaryk University","startDate":"2020-06-16","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug","enrollment":150},{"nctId":"NCT04313634","phase":"PHASE2","title":"Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans","status":"COMPLETED","sponsor":"Sundeep Khosla, M.D.","startDate":"2020-06-09","conditions":"Healthy","enrollment":74},{"nctId":"NCT04580121","phase":"PHASE1","title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-11-04","conditions":"Acute Myeloid Leukemia","enrollment":59},{"nctId":"NCT01514864","phase":"PHASE2","title":"Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05-31","conditions":"Carcinoma, Non-small Cell Lung","enrollment":19},{"nctId":"NCT06145217","phase":"PHASE1","title":"An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®","status":"COMPLETED","sponsor":"Xspray Pharma AB","startDate":"2023-08-22","conditions":"Drug-drug Interaction Study","enrollment":18},{"nctId":"NCT03625388","phase":"PHASE2","title":"Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2018-11-05","conditions":"Chronic Myelogenous Leukemia","enrollment":56},{"nctId":"NCT04681820","phase":"","title":"Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-11-01","conditions":"CML-CP; Mutation;Suboptimal Response or Failure in TKI","enrollment":200},{"nctId":"NCT01593254","phase":"PHASE2","title":"Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-09-12","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":262},{"nctId":"NCT00529763","phase":"PHASE2","title":"Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11-17","conditions":"Leukemia","enrollment":121},{"nctId":"NCT05640804","phase":"PHASE1","title":"A Bioequivalence Study of Dasatinib Tablet","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-09-09","conditions":"Leukemia, Myelogenous, Chronic","enrollment":56},{"nctId":"NCT01850004","phase":"PHASE2","title":"Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-01-22","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":84},{"nctId":"NCT05439408","phase":"PHASE1","title":"Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Xspray Pharma AB","startDate":"2021-06-07","conditions":"Biological Availability","enrollment":110},{"nctId":"NCT05433896","phase":"PHASE1","title":"Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Xspray Pharma AB","startDate":"2020-11-01","conditions":"Pharmacokinetics, Drug Interactions","enrollment":17},{"nctId":"NCT01460160","phase":"PHASE2","title":"Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-04-13","conditions":"Leukemia, Pediatric","enrollment":106},{"nctId":"NCT05024357","phase":"NA","title":"A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-09-06","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult","enrollment":80},{"nctId":"NCT02596828","phase":"PHASE2","title":"Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2016-04","conditions":"Pineoblastoma","enrollment":4},{"nctId":"NCT04925141","phase":"PHASE4","title":"A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2016-05-10","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":62},{"nctId":"NCT00306202","phase":"PHASE1","title":"Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-03-31","conditions":"Leukemia","enrollment":63},{"nctId":"NCT01207440","phase":"PHASE2","title":"Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","startDate":"2010-09-30","conditions":"Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia","enrollment":449},{"nctId":"NCT01467986","phase":"PHASE2","title":"Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2013-08","conditions":"Neuroblastoma Recurrent","enrollment":130},{"nctId":"NCT00780676","phase":"PHASE2","title":"Personalized Treatment Selection for Metastatic Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Breast Cancer","enrollment":97},{"nctId":"NCT01876212","phase":"PHASE2","title":"Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma","status":"COMPLETED","sponsor":"Walter J. Storkus","startDate":"2014-05-16","conditions":"Metastatic Melanoma","enrollment":15},{"nctId":"NCT03414450","phase":"PHASE1","title":"Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies","status":"WITHDRAWN","sponsor":"EDDC (Experimental Drug Development Centre), A*STAR Research Entities","startDate":"2018-04-25","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Ph- Acute Lymphoblastic Leukemia (Ph-ALL), Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)","enrollment":""},{"nctId":"NCT02233049","phase":"PHASE2","title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication","status":"UNKNOWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-10","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":250},{"nctId":"NCT03205267","phase":"PHASE2","title":"Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients","status":"UNKNOWN","sponsor":"University of Bonn","startDate":"2016-03","conditions":"Chronic Myelogenous Leukaemia","enrollment":127},{"nctId":"NCT00538980","phase":"PHASE2","title":"Dasatinib in Polycythemia Vera","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-04-30","conditions":"Polycythemia Vera","enrollment":10},{"nctId":"NCT01357655","phase":"PHASE2","title":"Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Leukemia","enrollment":70},{"nctId":"NCT00560352","phase":"PHASE1","title":"Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":16},{"nctId":"NCT00481247","phase":"PHASE3","title":"A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-09","conditions":"Myeloid Leukemia, Chronic","enrollment":547},{"nctId":"NCT01660906","phase":"PHASE4","title":"Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-12","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":39},{"nctId":"NCT00123474","phase":"PHASE3","title":"Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"Myeloid Leukemia, Chronic, Chronic-Phase","enrollment":724},{"nctId":"NCT01218477","phase":"PHASE1, PHASE2","title":"Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-01","conditions":"Leukemia","enrollment":33},{"nctId":"NCT00696072","phase":"PHASE2","title":"Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT00754325","phase":"PHASE2","title":"Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-09","conditions":"Advanced Breast Cancer","enrollment":100},{"nctId":"NCT00982488","phase":"PHASE2","title":"Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-10","conditions":"Leukemia","enrollment":238},{"nctId":"NCT01169753","phase":"NA","title":"Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05","conditions":"Chronic Myeloid Leukemia","enrollment":1},{"nctId":"NCT00452673","phase":"PHASE1","title":"Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Advanced Breast Cancer","enrollment":52},{"nctId":"NCT00500006","phase":"PHASE1","title":"A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Chronic Myelogenous Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive","enrollment":3},{"nctId":"NCT00123487","phase":"PHASE3","title":"Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-06","conditions":"Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive","enrollment":638},{"nctId":"NCT00924352","phase":"PHASE1, PHASE2","title":"Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2009-06","conditions":"Metastatic Breast Cancer","enrollment":56},{"nctId":"NCT00439270","phase":"PHASE1, PHASE2","title":"Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-07","conditions":"Metastatic Prostate Cancer","enrollment":49},{"nctId":"NCT00858403","phase":"PHASE2","title":"Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-03","conditions":"Lung Cancer","enrollment":7},{"nctId":"NCT00320190","phase":"PHASE2","title":"Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2006-08","conditions":"Leukemia, Myeloid, Chronic","enrollment":52},{"nctId":"NCT00872976","phase":"PHASE1","title":"Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT00385580","phase":"PHASE2","title":"Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-01","conditions":"Prostate Cancer","enrollment":94},{"nctId":"NCT00767520","phase":"PHASE2","title":"Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02","conditions":"Breast Cancer","enrollment":155},{"nctId":"NCT01392703","phase":"PHASE1","title":"Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-07","conditions":"Pharmacokinetic Study in Healthy Participants","enrollment":141},{"nctId":"NCT00672295","phase":"PHASE1","title":"PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer","status":"COMPLETED","sponsor":"AA Secord","startDate":"2007-08","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":11},{"nctId":"NCT00948389","phase":"PHASE1, PHASE2","title":"Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2009-10","conditions":"Glioblastoma","enrollment":28},{"nctId":"NCT00101660","phase":"PHASE2","title":"Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia","enrollment":387},{"nctId":"NCT00764309","phase":"PHASE1, PHASE2","title":"Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-01","conditions":"Scleroderma","enrollment":47},{"nctId":"NCT00895297","phase":"PHASE2","title":"Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2010-02","conditions":"Chronic Myeloid Leukemia","enrollment":50},{"nctId":"NCT00978731","phase":"PHASE1","title":"Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-12","conditions":"Leukemia","enrollment":46},{"nctId":"NCT00371345","phase":"PHASE2","title":"Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Breast Cancer, Metastasis","enrollment":92},{"nctId":"NCT00099606","phase":"PHASE1","title":"Phase I (PH I) Mad Refractory Solid Tumor Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-07","conditions":"Neoplasms","enrollment":60},{"nctId":"NCT00101647","phase":"PHASE2","title":"Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-12","conditions":"Chronic Myelogenous Leukemia","enrollment":197},{"nctId":"NCT00162214","phase":"PHASE1","title":"Study of Dasatinib in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2005-08","conditions":"Tumors","enrollment":60},{"nctId":"NCT00382668","phase":"","title":"A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-10","conditions":"Liver Diseases","enrollment":40},{"nctId":"NCT00103701","phase":"PHASE1","title":"BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-11","conditions":"Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive","enrollment":""},{"nctId":"NCT00337454","phase":"PHASE1, PHASE2","title":"Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"Chronic Myelogenous Leukemia","enrollment":48},{"nctId":"NCT00101595","phase":"PHASE2","title":"Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-01","conditions":"Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive","enrollment":96},{"nctId":"NCT00371254","phase":"PHASE2","title":"A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Breast Cancer, Metastasis","enrollment":55},{"nctId":"NCT00482703","phase":"PHASE1, PHASE2","title":"A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-05","conditions":"Myeloid Leukemia, Chronic","enrollment":23},{"nctId":"NCT00339144","phase":"PHASE1","title":"Study of Dasatinib (BMS-354825) in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-01","conditions":"Tumors","enrollment":16},{"nctId":"NCT01030718","phase":"PHASE1, PHASE2","title":"Rollover Study of BMS-354825 in Patients With CML and Ph+ALL","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-01","conditions":"Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT00101816","phase":"PHASE2","title":"Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-12","conditions":"Chronic Myeloid Leukemia, Blast Crisis","enrollment":124},{"nctId":"NCT00103844","phase":"PHASE2","title":"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia","enrollment":150},{"nctId":"NCT00298987","phase":"PHASE2","title":"A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-02","conditions":"Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2","enrollment":400},{"nctId":"NCT00655746","phase":"PHASE1","title":"The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-04","conditions":"Healthy","enrollment":14},{"nctId":"NCT00362466","phase":"PHASE3","title":"A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Leukemia","enrollment":3}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CHYLOTHORAX"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"BONE MARROW FAILURE"},{"count":1,"reaction":"DRUG EFFECT INCOMPLETE"},{"count":1,"reaction":"DRUG INTOLERANCE"},{"count":1,"reaction":"DRUG RESISTANCE"},{"count":1,"reaction":"ESCHERICHIA SEPSIS"},{"count":1,"reaction":"GROWTH RETARDATION"},{"count":1,"reaction":"LEUKAEMIA RECURRENT"},{"count":1,"reaction":"MULTIPLE ORGAN DYSFUNCTION SYNDROME"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dasatinib Tablets","genericName":"Dasatinib Tablets","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival. Used for Chronic myeloid leukemia (CML), chronic phase, accelerated phase, and blast crisis, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}